Sarepta Therapeutics, Inc.

SRPT
As of the close on Sep 25, 2026
Price
$18.67
Market cap
$1.97B
P/E (diluted TTM)
—
Not meaningful: the last four quarters were a loss
EPS (TTM)
−$1.60
Four quarters to Jun 30, 2026
Dividend yield
—
Dividend records do not yet cover the latest payments

Figures shown here come from public SEC filings. Dates beside each section show the available history.

How Sarepta Therapeutics, Inc. Makes Money

Follow each dollar of revenue through to what shareholders keep.

From revenue to net income

Pick a year or quarter. Each band's width is its dollar amount.

Source: Sarepta Therapeutics, Inc. — 10-Q filed Aug 5, 2026

Financial Summary

Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.

Loading financial history…

SEC filings supply these figures; updates after the dates shown are not included. This page includes 16 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 5, 2026.

Ownership

Who holds the shares, as reported in SEC ownership filings.

Unusually large insider trades

Each trade is compared with the other insider trades of the same kind in the same security among Sarepta Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.

  • 2025-12-16 · Estepan Ian Michael: Larger than 27 of the 28 other insider sales of Common Stock on file. SEC filing
  • 2024-06-25 · Brown Ryan Edward: Larger than all 28 other insider sales of Common Stock on file. SEC filing
  • 2024-03-08 · Wigzell Hans Lennart Rudolf: Larger than 26 of the 28 other insider sales of Common Stock on file. SEC filing

Purchases & sales (open market or private)

SecurityCodePriceFiling
2026-03-12Mayo Stephen · DirectorCommon StockS — Open market or private sale−7,23917.02SEC filing
2025-12-16Estepan Ian Michael · Chief Operating OfficerCommon StockS — Open market or private sale−13,18722.31SEC filing
2025-03-12Nicaise Claude · DirectorCommon StockS — Open market or private sale−2,49199.64SEC filing
2024-12-12Wigzell Hans Lennart Rudolf · DirectorCommon StockS — Open market or private sale−10,500124.84SEC filing
2024-12-05Boor Kathryn Jean · DirectorCommon StockS — Open market or private sale−1,636125.55SEC filing
2024-08-30Estepan Ian Michael · Chief Financial OfficerCommon StockS — Open market or private sale−5,985137.36SEC filing
2024-08-16Chambers Michael Andrew · DirectorCommon StockP — Open market or private purchase+5,648134.66SEC filing
2024-08-16Chambers Michael Andrew · DirectorCommon StockP — Open market or private purchase+18,284134.06SEC filing

Showing 8 of 13 rows

Grants, exercises, tax & gifts

SecurityCodeFiling
2026-06-04Barry Richard · DirectorCommon StockA — Grant, award, or other acquisition+16,875SEC filing
2026-06-04BEHRENS M KATHLEEN · DirectorCommon StockA — Grant, award, or other acquisition+16,875SEC filing
2026-06-04Nicaise Claude · DirectorCommon StockA — Grant, award, or other acquisition+16,875SEC filing
2026-06-04Boor Kathryn Jean · DirectorCommon StockA — Grant, award, or other acquisition+16,875SEC filing
2026-06-04Mayo Stephen · DirectorCommon StockA — Grant, award, or other acquisition+16,875SEC filing
2026-06-04Chambers Michael Andrew · DirectorCommon StockA — Grant, award, or other acquisition+16,875SEC filing
2026-06-04Connelly Deirdre P · DirectorCommon StockA — Grant, award, or other acquisition+16,875SEC filing
2026-06-04Wigzell Hans Lennart Rudolf · DirectorCommon StockA — Grant, award, or other acquisition+16,875SEC filing

Showing 8 of 32 rows

Other activity

SecurityCodeFiling
2025-12-18Chambers Michael Andrew · DirectorConvertible Senior NotesD — Disposition to the issuer−unknownSEC filing

Showing 1 of 1 rows

These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.